Anaplastic large-cell lymphoma, T-/null-cell type

Oncologist

Volumn 11, Issue 7, 2006, Pages 831-840

  Jacobsen, Eric ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

ALK; Anaplastic large cell lymphoma; Cutaneous lymphoma; Lymphomatoid papulosis

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ALKYLATING AGENT; BLEOMYCIN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; SGN 30; TRIMETREXATE; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE; VORINOSTAT;

ANAPLASTIC CARCINOMA; CELL TYPE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; HISTOLOGY; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL; T LYMPHOCYTE;

HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, LARGE-CELL, KI-1;

EID: 33746620596     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-7-831     Document Type: Review

References (95)

1. Kadin ME, Morris SW. The t(2;5) in human lymphomas. Leuk Lymphoma 1998;29:249-256.
2. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.
3. Sandlund JT, Pui CH, Santana VM et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994;12:895-898.
4. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697-2706.
5. Herling M, Rassidakis GZ, Jones D et al. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol 2004;35:455-459.
6. Noorali S, Pervez S, Yaqoob N et al. Prevalence and characterization of anaplastic large cell lymphoma and its association with Epstein-Barr virus in Pakistani patients. Pathol Res Pract 2004;200:669-679.
7. Costes-Martineau V, Delfour C, Obled S et al. Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review. J Clin Pathol 2002;55:868-871.
8. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
9. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
10. Kumar S, Pittaluga S, Raffeld M et al. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 2005;8:52-60.
11. Willemze R, Meijer CJ. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 2003;17:1319-1332, vii-viii.
12. Shehan JM, Kalaaji AN, Markovic SN et al. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol 2004;51:103-110.
13. Herrera E, Gallardo M, Bosch R et al. Primary cutaneous CD30 (Ki-1)-positive non-anaplastic B-cell lymphoma. J Cutan Pathol 2002;29:181-184.
14. Liu HL, Hoppe RT, Kohler S et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Acad Am Dermatol 2003;49:1049-1058.
15. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-3661.
16. Cabanillas F, Armitage J, Pugh WC et al. Lymphomatoid papulosis: a Tcell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med 1995;122:210-217.
17. DeCoteau JF, Butmarc JR, Kinney MC et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996;87:3437-3441.
18. de Bruin PC, Beljaards RC, van Heerde P et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993;23:127-135.
19. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol 2002;118:773-779.
20. Wellmann A, Thieblemont C, Pittaluga S et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 2000;96:398-404.
21. Filippa DA, Ladanyi M, Wollner N et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 1996;87:2905-2917.
22. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003;40:244-256.
23. Noorduyn LA, van Heerde P, Meyer CJ. Cytology of Ki-1 (CD-30) positive large cell lymphoma. Cytopathology 1990;1:297-304.
24. Greer JP, Kinney MC, Collins RD et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 1991;9:539-547.
25. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91:2076-2084.
26. Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988;12:264-274.
27. Rosso R, Paulli M, Magrini U et al. Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/Leu-M1 antigen. Immunohistochemical and morphological relationships to Hodgkin's disease. Virchows Arch A Pathol Anat Histopathol 1990;416:229-235.
28. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175-184.
29. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001;54:933-939.
30. Foss HD, Anagnostopoulos I, Araujo I et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996;88:4005-4011.
31. Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol 2004;121:709-717.
32. Burns BF, Dardick I. Ki-1-positive non-Hodgkin's lymphomas. An immunophenotypic, ultrastructural, and morphometric study. Am J Clin Pathol 1990;93:327-332.
33. Downing JR, Shurtleff SA, Zielenska M et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase- polymerase chain reaction. Blood 1995;85:3416-3422.
34. Drexler HG, Gignac SM, von Wasielewski R et al. Pathobiology of NPMALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000;14:1533-1559.
35. Chiarle R, Gong JZ, Guasparri I et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003;101:1919-1927.
36. Kuefer MU, Look AT, Pulford K et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997;90:2901-2910.
37. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 1999;11:490-496.
38. Lai R, Rassidakis GZ, Medeiros LJ et al. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol 2004;164:2251-2258.
39. Zamo A, Chiarle R, Piva R et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-1047.
40. Chiarle R, Simmons WJ, Cai H et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11:623-629.
41. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-310.
42. De Paepe P, Baens M, van Krieken H et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638-2641.
43. Lucet IS, Fantino E, Styles M et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107:176-183.
44. Falini B, Bigerna B, Fizzotti M et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 1998;153:875-886.
45. Wlodarska I, De Wolf-Peeters C, Falini B et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998;92:2688-2695.
46. Bischof D, Pulford K, Mason DY et al. Role of nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic kinase fusion protein in oncogenesis. Mol Cell Biol 1997;17:2312-2325.
47. Pulford K, Falini B, Cordell J et al. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol 1999; 154:1657-1663.
48. Touriol C, Greenland C, Lamant L et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-3207.
49. Pulford K, Lamant L, Morris S et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-1404.
50. Falini B, Pulford K, Pucciarini A et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999;94:3509-3515.
51. Zettl A, Rudiger T, Konrad MA et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004;164:1837-1848.
52. Gascoyne RD, Lamant L, Martin-Subero JI et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003;102:2568-2573.
53. Ruchatz H, Coluccia AM, Stano P et al. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol 2003;31:309-315.
54. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-3921.
55. Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96:2993-3000.
56. Rassidakis GZ, Goy A, Medeiros LJ et al. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma, Clin Cancer Res 2003;9:2213-2220.
57. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
58. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
59. Schlette EJ, Medeiros LJ, Goy A et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-1688.
60. Janik JE, Morris JC, Pittaluga S et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 2004;104:3355-3357.
61. ten Berge RL, Meijer CJ, Dukers DF et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002;99:4540-4546.
62. Kaufmann TP, Coleman M, Nisce LZ. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Cancer Invest 1997;15:91-97.
63. Hoppe RT, Fuks Z, Bagshaw MA. Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:625-632.
64. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470-481.
65. Sarris AH, Phan A, Duvic M et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol 2002;20:2876-2880.
66. Didona B, Benucci R, Amerio P et al. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004;150:1198-1201.
67. Muto A, Nakagawa A, Shimomura Y et al. Antineoplastic agents for pediatric anaplastic large cell lymphoma: vinblastine is the most effective in vitro. Leuk Lymphoma 2005;46:1489-1496.
68. Williams DM, Hobson R, Imeson J et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002;117:812-820.
69. Seidemann K, Tiemann M, Schrappe M et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001;97:3699-3706.
70. Zinzani PL, Martelli M, Magagnoli M et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 1998;92:790-794.
71. Tilly H, Gaulard P, Lepage E et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997;90:3727-3734.
72. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
73. Jagasia M, Morgan D, Goodman S et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004;45:2261-2267.
74. Jantunen E, Wiklund T, Juvonen E et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004;33:405-410.
75. Zamkoff KW, Matulis MD, Mehta AC et al. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplantation 2004;33:635-638.
76. Fanin R, Ruiz de Elvira MC, Sperotto A et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23:437-442.
77. Deconinck E, Lamy T, Foussard C et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109:736-742.
78. Fanin R, Silvestri F, Geromin A et al. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation. Blood 1996;87:1243-1248.
79. Fanin R, Sperotto A, Silvestri F et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma 1999;35:159-169.
80. Bordon V, De Paepe P, Dhooge C et al. Successful treatment with allogeneic bone marrow transplantation of an early relapse of ALK-positive anaplastic large cell lymphoma. Haematologica 2005;90:ECR19.
81. Liso A, Tiacci E, Binazzi R et al. Haploidentical peripheral-blood stemcell transplantation for ALK-positive anaplastic large-cell lymphoma. Lancet Oncol 2004;5:127-128.
82. Borchmann P, Treml JF, Hansen H et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742.
83. Heuck F, Ellermann J, Borchmann P et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother 2004;27:347-353.
84. Bartlett NL, Younes A, Carabasi MA et al. Phase I study of SGN-30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2002;100:362a-363a.
85. Ansell SM, Byrd JC, Horwitz SM et al. Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma. Blood 2004;104:2636a.
86. Schnell R, Dietlein M, Staak JO et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-4678.
87. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma 2004;5:190-193.
88. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-48.
89. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
90. Ryan QC, Headlee D, Acharya M et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma, J Clin Oncol 2005;23:3912-3922.
91. Plumb JA, Finn PW, Williams RJ et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-728.
92. Byrd JC, Marcucci G, Parthun MR et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105:959-967.
93. Mathas S, Jöhrens K, Joos S et al. Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005;106:4287-4293.
94. Rebollo A, Dumoutier L, Renauld JC et al. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 2000;20:3407-3416.
95. Wan W, Albom MS, Lu L et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006;107:1617-1623.